MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ITCI Intra-Cellular Therapies
- 83.450
- -0.690-0.82%
Close Dec 20 16:00 ET
- 83.450
- 0.0000.00%
Post 20:01 ET
8.85BMarket Cap-95.92P/E (TTM)
85.030High82.760Low1.12MVolume84.540Open84.140Pre Close93.87MTurnover1.08%Turnover RatioLossP/E (Static)106.02MShares93.45052wk High7.73P/B8.66BFloat Cap62.78052wk Low--Dividend TTM103.74MShs Float93.450Historical High--Div YieldTTM2.70%Amplitude6.750Historical Low83.779Avg Price1Lot Size
Intra-Cellular Therapies Key Stats
EPS
According to the latest financial report of Intra-Cellular Therapies, the latest earnings per share (TTM) for the company is -0.25. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Intra-Cellular Therapies's free cash flow? The latest report shows it as -27.22M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Intra-Cellular Therapies shows that the company's current ratio is 7.66, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Intra-Cellular Therapies, the quick ratio is 6.94, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Intra-Cellular Therapies? The latest ROE figure is -2.30%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Intra-Cellular Therapies, the total asset return on investment (ROA) is -1.99%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Intra-Cellular Therapies's latest financial report to see how their gross margin is doing - currently at 91.26%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Intra-Cellular Therapies, the net profit margin is -15.01%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.